Yang DL, Li YF, Li YJ, Qiu GG, et al. Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details. Hepatology 2025 May 9. doi: 10.1097/HEP.0000000000001395.
PMID: 40344527